Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder inject
| Current Price | ₹996.50 |
|---|---|
| Market Cap | ₹5,836 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Domestic contract manufacturers |
| P/E Ratio | 40.7 |
| Return on Equity | 14.03% |
| 52-Week Range | ₹622.00 – ₹1,353.50 |
| Beta (1Y) | 0.53 |
| Dividend Yield | 0.40% |
| Revenue | ₹471 Cr |
|---|---|
| Net Profit | ₹44 Cr |
| EPS (Basic) | ₹7.71 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
1. Drugs and Pharmaceutical Products-100%
INNOVA CAPTAB LIMITED is trading at ₹996.50, with a market capitalisation of ₹5,836 Cr.
INNOVA CAPTAB LIMITED operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Domestic contract manufacturers).
INNOVA CAPTAB LIMITED has a P/E of 40.7 and a return on equity of 14.03%.
In Q1 FY27, INNOVA CAPTAB LIMITED reported revenue of ₹471 Cr and net profit of ₹44 Cr, with basic EPS of ₹7.71 (consolidated, parsed from the company's exchange filing).